GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln
GSK to pay $70 million to settle whistleblower lawsuit
Pfizer and Sanofi also settling Zantac cases
Boehringer Ingelheim faces trial, denies wrongdoing
New throughout, adds detail on litigation, statements from plaintiffs and GSK
By Brendan Pierson
Oct 9 (Reuters) -GSK GSK.L has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.
The agreement with 10 plaintiffs' law firms resolves about 80,000 cases, or 93% of cases pending against the British drugmaker in state courts nationwide, the company said. GSK also said it would pay $70 million to settle a related whistleblower lawsuit filed by a Connecticut laboratory.
GSK did not admit wrongdoing as part of the deal, saying in a statement that there was "no consistent or reliable evidence" that ranitidine, the drug's active ingredient, increased the risk of cancer. However, it said the settlements were in the best long-term interest of the company to avoid the risk of continuing litigation.
Jennifer Moore and R. Brent Wisner, lead attorneys for the plaintiffs, said in a joint statement that they were "thrilled" with the deal.
First approved by U.S. regulators in 1983, Zantac became the world's best-selling medicine in 1988 and one of the first to top $1 billion in annual sales. The drug was sold at different times by pharmaceutical companies GSK, Pfizer PFE.N, Sanofi SASY.PA and Boehringer Ingelheim.
Lawsuits against the companies began piling up in both state and federal courts after the U.S. Food and Drug Administration in 2020 asked manufacturers to pull Zantac off the market. The agency cited concerns that ranitidine could degrade into NDMA, a carcinogen, over time or when exposed to heat.
Pfizer has agreed to settle most of the Zantac cases against it in state court, according to its most recent financial statement, and Sanofi in April announced that it was settling about 4,000 cases.
Boehringer Ingelheim has not announced any major settlements, but is currently facing a trial over the drug in Oakland, California, state court. The company has denied wrongdoing.
"We continue to pursue claims against Boehringer Ingelheim for its wrongdoing for exposing millions of people to a known carcinogen for over a decade," Moore and Wisner said.
A majority of the remaining state court cases are in Delaware, where a judge in June allowed plaintiffs to present crucial expert testimony that Zantac caused cancer. The drug companies had sought to keep that testimony out saying it was not based on sound scientific evidence, which would have ended the lawsuits, and are appealing the judge's ruling to the Delaware Supreme Court.
The companies won a major victory in 2022 when a Florida federal court judge ruled that about 50,000 cases centralized there could not go forward because the plaintiffs' expert testimony was not supported by reliable science. About 14,000 of those cases are being appealed, and are not part of Wednesday's settlement.
A drug currently sold under the name Zantac 360 uses a different active ingredient and contains no ranitidine.
Reporting by Brendan Pierson in New York and Aatrayee Chatterjee in Bengaluru; Editing by Aurora Ellis and Alexia Garamfalvi
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
